Psöriatik Artrit ve D Vitamini
Özet
Psöriyatik artrit (PsA), psöriyazis (sedef hastalığı) ile ilişkili, periferik ve aksiyel eklemleri tutan inflamatuar bir artropatidir. Genetik, immünolojik ve çevresel faktörlerin tetiklediği bu hastalıkta, T hücre hiperaktivasyonu ve Th-1 yolağı baskınlığı ile birçok proinflamatuar sitokin (TNF-α, IFN-γ, IL-17 vb.) artış gösterir. Klasik olarak kalsiyum ve fosfat metabolizmasını düzenleyen D vitamini, bağışıklık hücrelerinde bulunan reseptörleri (VDR) aracılığıyla immünomodülatör ve immünsupresif etkiler sergiler. Makrofajlardan antijen sunumunu azaltarak, T ve B lenfosit aktivasyonunu baskılayarak ve antienflamatuar sitokinleri düzenleyerek otoimmün yanıtı kontrol eder. Psöriyazis ve PsA hastalarında D vitamini eksikliğinin (hipovitaminöz D) sıklıkla görüldüğü, serum 25-(OH)D3 seviyelerindeki düşüklüğün cilt tutulumunun şiddeti, yüksek CRP düzeyleri ve artmış hastalık aktivitesi ile ilişkili olduğu bildirilmiştir. Kadın hastalarda eksiklik riski daha yüksektir. Tarihsel süreçte 1930'lardan itibaren oral ve topikal D vitamini tedavileri denenmiş; kalsitriol gibi aktif formların keratinosit proliferasyonunu inhibe ettiği ve PsA'li hastalarda eklem hassasiyeti ile ağrı düzeylerinde klinik iyileşme sağladığı gösterilmiştir. Günümüzde 0,25-2 µg/gün veya aylık 40.000-100.000 IU dozlarında D vitamini desteği uygulanmaktadır. D vitamininin antienflamatuar ve antiproliferatif özellikleri, bu kronik inflamatuar hastalıkların prognozunu olumlu etkileme ve kötü gidişatı azaltma potansiyeline sahiptir.
Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with psoriasis, affecting peripheral and axial joints, driven by genetic, immunologic, and environmental factors that trigger T-cell hyperactivity and Th-1 pathway dominance, leading to elevated proinflammatory cytokines. Beyond its classic role in calcium homeostasis, vitamin D acts as an immunomodulatory hormone through vitamin D receptors (VDR) on immune cells, suppressing antigen presentation, inhibiting lymphocyte activation, and regulating cytokine production. Studies consistently demonstrate a high prevalence of vitamin D deficiency (hypovitaminosis D) in PsA and psoriasis patients, where lower serum 25-(OH)D3 levels correlate significantly with increased disease activity, higher CRP levels, and greater severity of skin involvement, particularly in female patients. Historical and contemporary clinical data since the 1930s indicate that oral and topical vitamin D therapies, including active forms like calcitriol, successfully inhibit keratinocyte proliferation and substantially improve joint tenderness and pain scores. Currently administered in therapeutic doses of 0.25-2 µg/day or 40,000-100,000 IU monthly, vitamin D leverages its potent anti-inflammatory and antiproliferative properties to modulate acquired immune responses, thereby offering a viable supportive strategy to reduce disease severity and optimize long-term prognostic outcomes in patients suffering from psoriatic arthritis.
Referanslar
Bruce IN. Psoriatic Arthritis: Clinical Features. In: Hochberg MC, Silman AJ, Smolen JS (Eds.). Rheumatology. 4th ed. 2008: 1165-76. Elsevier, Philadelphia
Hakim A, Clunie GPR, Haq I. Oxford handbook of rheumatology (second edit). 2008. Oxford University Press, Oxford
Arasıl T. Psöriatik Artrit. Beyazova M, Gökçe Kutsal Y, editörler. Fiziksel Tıp ve Rehabilitasyon. 2. Baskı. 2011: 1598-605. Güneş Kitapevi, Ankara
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018; 391:2273-84.
Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65-70.
Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-66.
Uğurlu H. Osteomalazi, Paget Hastalığı. Beyazova M, Gökçe-Kutsal editörler. Fiziksel Tıp ve Rehabilitasyon. 2. Baskı. 2011: 1895-98.Güneş Kitabevi, Ankara
Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab. 2011;25(4):531-41.
Haussler MR, Whitfield GK, Kaneko I, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77-98.
Pelajo CF, Lopez-Benitez JM, Miller LC. Vitamin D and Autoimmune Rheumatologic Disorders. Autoimmun Rev. 2010;9(7):507-510.
Rosen Y, Daich J, Soliman I, et al. Vitamin D and autoimmunity. Scand J Rheumatol. 2016;45(6):439-47.
Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc. 2012;71(1):50-61.
Yin K, Agrawal DK. Vitamin D and inflammatory diseases. J Inflamm Res. 2014;7:69-87.
Kechichian E, Ezzedine K. Vitamin D and the Skin: An Update for Dermatologists. Am J Clin Dermatol. 2018;19(2):223-35.
Krafka J. A Simple Treatment for Psoriasis. J. Clin. Lab. Med. 1936; 21:1147–8.
Rappaport BZ, Reed CI, Hathaway ML, Struck HC. The Treatment of Hay Fever and Asthma with Viosterol of High Potency. J. Allergy. 1935;5:541–53.
Dreyer I., Reed C. The Treatment of Arthritis with Massive Doses of Vitamin D. Arch. Phys.Ther. 1935;16:537–43.
Howard JE, Meyer RJ. Intoxication with vitamin D. J. Clin. Endocrinol. 1948;8:895–910.
Morimoto S, Kumahara Y. A Patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med. J. Osaka Univ. 1985;35:51–4.
Morimoto S, Yoshikawa K, Kozuka T, et al. open study of vitamin D3 treatment in psoriasis vulgaris. Br. J. Dermatol. 1986;115:421–9.
Takamoto S, Onishi T, Moromoto S, et al. Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: A pilot study. Calcif. Tissue Int. 1986;39:360–4.
Morimoto S, Yoshikawa K, Kozuka T, et al. Treatment of psoriasis vulgaris with oral 1 alpha,25-dihydroxyvitamin D3—Report of two cases. J. Dermatol. 1987;14:59–62.
Holick MF, Smith E, Pincus S. Skin as the Site of Vitamin D Synthesis and Target Tissue for 1,25-Dihydroxyvitamin D3 Use of Calcitriol (1,25-Dihydroxyvitamin D3) for Treatment of Psoriasis. Arch. Dermatol. 1987;123:1677–83a.
Huckins D, Felson D, Holick MF. Treatment of Psoriatic Arthritis with Oral 1,25-dihydroxyvitamin D3: A Pilot Study. Arthritis Rheum. 1990;33:1723–7.
Stanescu AMA, Simionescu AA, Diaconu CC. Oral Vitamin D Therapy in Patients with Psoriasis. Nutrients. 2021;13(1):163.
Yin K, Agrawal DK. Vitamin D and inflammatory diseases. J Inflamm Res. 2014;7:69-87.
Kechichian E, Ezzedine K. Vitamin D and the Skin: An Update for Dermatologists. Am J Clin Dermatol. 2018;19(2):223-35.
Orgaz-Molina J, Magro-Checa C, Rosales-Alexander JL, et al. Association of 25-hydroxyvitamin D serum levels and metabolic parameters in psoriatic patients with and without arthritis. J Am Acad Dermatol. 2013;69(6):938-46.
Kincse G, Bhattoa PH, Herédi E, et al. Vitamin D3 levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis. J Dermatol. 2015;42(7):679-84.
Gaál J, Lakos G, Szodoray P, et al. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol. 2009;89(2):140-4.
Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54(4):383-92.
Sağ MS, Sağ S, Tekeoğlu İ, et al. Comparison of 25-hidroksi Vitamin D serum concentrations in patients with psoriasis and psoriatic arthritis. J Back Musculoskelet Rehabil. 2018;31(1):37-43.
Yin K, Agrawal DK. Vitamin D and inflammatory diseases. J Inflamm Res. 2014;7:69-87.
Kechichian E, Ezzedine K. Vitamin D and the Skin: An Update for Dermatologists. Am J Clin Dermatol. 2018;19(2):223-35.
Liu W, Zhang L, Xu HJ, et al. The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis. Int J Mol Sci. 2018;19(9):2736.
Umar M, Sastry KS, Al Ali F, et al. Vitamin D and the Pathophysiology of Inflammatory Skin Diseases. Skin Pharmacol Physiol. 2018;31(2):74-86.
Oten E, Başkan B, Sivas F, Bodur H. Relation Between Osteoporosis and Vitamin D Levels and Disease Activity in Psoriatic Arthritis. Erciyes Med J. 2017; 39(3): 94-100.
Chandrashekar L, Kumarit GR, Rajappa M, et al. DM. 25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. Br J Biomed Sci. 2015;72:56–60.
